Drug data last refreshed 14h ago · AI intelligence enriched 2mo ago
AIR is an inhaled gas product approved by the FDA in February 2026, representing a novel delivery modality for therapeutic intervention. The mechanism of action and specific clinical indications have not been disclosed in available data, making this an emerging asset with limited public information.
Early-stage launch asset with moderate competitive pressure (30/100) suggests controlled but active market positioning; commercial infrastructure is being built.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia
Tapestry Rotator Cuff Repair PMCF
Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function
A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment
Trans STAIR: Implementing an Evidence Based Trauma Treatment With Community Led PrEP Navigation
Worked on AIR at Connect Biopharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Connect Biopharma is hiring 1 role related to this product
AIR represents a launch-stage opportunity with modest current job activity but high growth potential as the product scales. Professionals joining now will have formative influence on brand positioning in a newly approved, non-crowded market segment.